![]() ![]() "Our VIAS Image Analysis System was the first entry into the digital pathology market and is now the leading system for automated image analysis in breast cancer. "Through this acquisition, Ventana is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," said Hany Massarany, President of Ventana Medical Systems, Inc. In addition, their products improve workflow efficiency in image archiving and retrieval, remote case review, and turnaround time. They also provide the software to view, analyze and manage tissue images using a computer, taking pathology beyond traditional microscope applications. ![]() In turn, BioImagene brings to Ventana additional capabilities for scanning and analysing tissue that are not possible in the glass-slide world."īioImagene's products create high-resolution, whole-slide digital images from glass microscope slides. "Ventana is already a leader in image analysis for breast cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories worldwide. "With its leadership position in pathology and its global reach, Ventana is the ideal partner for BioImagene," commented Ajit Singh, CEO of BioImagene, Inc. BioImagene products will complement and strengthen our current offering in image analysis and information management." "The increasing complexity of new tests and technologies creates tremendous need for more sophisticated tools for tissue analysis and diagnosis. ![]() "As part of the personalised healthcare approach, pathologists are increasingly involved in generating information with high impact on treatment decisions," said Daniel O'Day, COO Roche Diagnostics. Digital pathology is a suite of dynamic, image-based technologies that enable image capture, information management, image analysis and virtual sharing of patients' tissue samples on glass slides. The transaction is subject to customary closing conditions and is expected to close in the coming weeks.īioImagene is an innovative leader in the field of digital pathology workflow and analysis. The purchase price is approximately 100 million US dollars on a debt-free basis. Roche announced recently that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California. The image analysis system can substitute for or support visual counting by a pathologist.Acquisition further strengthens Roche's global leadership in tissue-based cancer diagnostics and research The performance of 30-9 is equivalent to that of MIB-1 in Ki67 assessment of breast cancer. Ki67-positive rates showed a strong correlation between the image analytical values and the pathologist-counted median values (r = 0.952). Between 30-9 and MIB-1, there was no significant difference of CV%, showing variabilities of Ki67-positive rates among pathologists. Ki67-positive rates by 30-9 showed a strong correlation with those by MIB-1 for all pathologists (pathologist #1: r = 0.985, pathologist #2: r = 0.987, pathologist #3: r = 0.982). In addition, the images of 30-9-stained slides were analyzed using the image analysis system, VENTANA Virtuoso. Three pathologists independently studied images of the counting areas to determine Ki67-positive rates. We scanned all the stained slides with Ventana iScan HT and selected the Ki67 counting areas based on morphological findings. The tissue sections were stained immunohistochemically with anti-Ki67 antibodies, 30-9 and MIB-1, as well as with hematoxylin and eosin for morphological analysis. We aimed to validate the performance of anti-Ki67 antibody clone 30-9 by comparison with clone MIB-1 and to investigate utility of the image analysis system in Ki67 assessment using clinical breast cancer samples.Ī series of sequential tissue sections was prepared from formalin-fixed paraffin-embedded blocks of surgically resected breast cancer specimens from 50 patients. Although Ki67 has important clinical relevance in breast cancer, its assessment results vary according to assay due to differences in both analytical and interpretation processes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |